RG
Redmile Group Portfolio holdings
AUM
$940M
This Quarter Return
+12.66%
1 Year Return
+75.78%
3 Year Return
+543.67%
5 Year Return
+585.96%
10 Year Return
+6,653.82%
AUM
$3.53B
AUM Growth
+$3.53B
(+3.1%)
Cap. Flow
-$35.7M
Cap. Flow
% of AUM
-1.01%
Top 10 Holdings %
Top 10 Hldgs %
48.03%
Holding
98
New
16
Increased
28
Reduced
21
Closed
18
Top Buys
| 1 |
Sarepta Therapeutics
SRPT
|
$62.6M |
| 2 |
TCDA
Tricida, Inc. Common Stock
TCDA
|
$57.4M |
| 3 |
Amicus Therapeutics
FOLD
|
$39.6M |
| 4 |
Centene
CNC
|
$36.2M |
| 5 |
Krystal Biotech
KRYS
|
$30.4M |
Top Sells
| 1 |
ARRY
Array Biopharma Inc
ARRY
|
$103M |
| 2 |
InflaRx
IFRX
|
$82.5M |
| 3 |
Xencor
XNCR
|
$58.3M |
| 4 |
Teva Pharmaceuticals
TEVA
|
$49.3M |
| 5 |
Penumbra
PEN
|
$47.5M |
Sector Composition
| 1 | Healthcare | 95.47% |
| 2 | Financials | 2.17% |
| 3 | Energy | 0.01% |
| 4 | Technology | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
ARRY
1
DELISTED
Array Biopharma Inc
ARRY
| $405M | 11.47% | 8,752,254 -2,218,264 | -20% | -$103M |
|
|
2
Amicus Therapeutics
FOLD
$2.34B
| $284M | 8.05% | 22,792,634 +3,176,572 | +16% | +$39.6M |
|
3
Fate Therapeutics
FATE
$120M
| $210M | 5.95% | 10,359,666 | – | – |
|
4
argenx
ARGX
$43.6B
| $151M | 4.28% | 1,068,832 +49,771 | +5% | +$7.05M |
|
5
uniQure
QURE
$896M
| $130M | 3.69% | 1,669,525 +362,003 | +28% | +$28.3M |
|
|
BOLD
6
DELISTED
Audentes Therapeutics, Inc
BOLD
| $113M | 3.18% | 2,972,167 +236,900 | +9% | +$8.97M |
|
|
EPZM
7
DELISTED
Epizyme, Inc
EPZM
| $110M | 3.1% | 8,729,142 +1,035,122 | +13% | +$13M |
|
|
ALLK
8
DELISTED
Allakos
ALLK
| $99.7M | 2.82% | 2,300,301 +465,891 | +25% | +$20.2M |
|
|
ALDR
9
DELISTED
Alder Biopharmaceuticals, Inc.
ALDR
| $97M | 2.75% | 8,244,896 | – | – |
|
10
Atara Biotherapeutics
ATRA
$84.6M
| $92.5M | 2.62% | 4,600,917 +115,500 | +3% | +$2.32M |
|
|
TCDA
11
DELISTED
Tricida, Inc. Common Stock
TCDA
| $76.8M | 2.17% | 1,945,200 +1,454,900 | +297% | +$57.4M |
|
12
eHealth
EHTH
$118M
| $76.5M | 2.17% | 888,705 -333,700 | -27% | -$28.7M |
|
13
Bristol-Myers Squibb
BMY
$96B
| $75.7M | 2.14% | 1,669,400 +69,700 | +4% | +$3.16M |
|
14
Tandem Diabetes Care
TNDM
$845M
| $75.2M | 2.13% | 1,166,032 +310,100 | +36% | +$20M |
|
15
Regenxbio
RGNX
$451M
| $71.5M | 2.02% | 1,391,376 -28,966 | -2% | -$1.49M |
|
16
Wave Life Sciences
WVE
$1.53B
| $71M | 2.01% | 2,719,707 -111,800 | -4% | -$2.92M |
|
|
WMGI
17
DELISTED
Wright Medical Group Inc
WMGI
| $70.7M | 2% | 2,372,157 -501,943 | -17% | -$15M |
|
|
18
Xencor
XNCR
$580M
| $66M | 1.87% | 1,612,798 -1,423,805 | -47% | -$58.3M |
|
|
19
Sarepta Therapeutics
SRPT
$1.78B
| $62.6M | 1.77% | +412,000 | New | +$62.6M |
|
20
Elevance Health
ELV
$71.8B
| $51.8M | 1.47% | 183,500 +6,800 | +4% | +$1.92M |
|
|
CELG
21
DELISTED
Celgene Corp
CELG
| $51.5M | 1.46% | 557,000 +21,300 | +4% | +$1.97M |
|
|
CLVS
22
DELISTED
Clovis Oncology, Inc.
CLVS
| $51.5M | 1.46% | 3,462,300 -1,101,629 | -24% | -$16.4M |
|
|
DCPH
23
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
| $50.1M | 1.42% | 2,223,376 +594,723 | +37% | +$13.4M |
|
24
Scholar Rock
SRRK
$3.14B
| $46.3M | 1.31% | 2,920,389 +869,300 | +42% | +$13.8M |
|
|
25
Krystal Biotech
KRYS
$4.27B
| $43.5M | 1.23% | 1,080,300 +755,800 | +233% | +$30.4M |
|